[Rationale for the use of systemic enzyme therapy in malignant diseases].
Miller
W
W
Schwerpunktpraxis für komplementäre Onkologie, Kempten/Allgäu. info@doktor-miller.de
D000284:Administration, Oral; D000818:Animals; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D010447:Peptide Hydrolases / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D011788:Quality of Life; D015996:Survival Rate; D016212:Transforming Growth Factor beta / Q000502:physiology; D000511:alpha-Macroglobulins / Q000378:metabolism
D016212:Transforming Growth Factor beta; D000511:alpha-Macroglobulins; D010447:Peptide Hydrolases